MedTrace Logo

Study of Cetuximab in Squamous Cell Carcinoma of the Skin Expressing EGFR

NCT00240682 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 37

Last updated 2012-02-22

No results posted yet for this study

Summary

The purpose of this study is to determine whether cetuximab is effective in the treatment of locally advanced or metastatic squamous cell carcinoma of the skin expressing EGFR.

Conditions

  • Skin Diseases
  • Carcinoma, Squamous Cell

Interventions

DRUG

cetuximab

Dosage form: bottles of 50 ml, 2 mg/ml; Dosage:400 mg/m2 initial dose followed by 250 mg/m2 by infusion every week; Number of Cycles : until progression or unacceptable toxicity develops.

Sponsors & Collaborators

  • Hospital of Chartres- France

    collaborator UNKNOWN

  • Centre Hospitalier of Chartres

    lead OTHER

Principal Investigators

  • Eve Maubec, MD · Dermatology Department, Hospital Bichat, Paris, France

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-10-31
Primary Completion
2009-04-30
Completion
2009-06-30

Countries

  • France

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00240682 on ClinicalTrials.gov